Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,961 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Acute exacerbation predicting poor outcomes in idiopathic interstitial pneumonia and advanced lung cancer patients undergoing cytotoxic chemotherapy.
Miyamoto A, Michimae H, Nakahara Y, Akagawa S, Nakagawa K, Minegishi Y, Ogura T, Hontsu S, Date H, Takahashi K, Homma S, Kishi K; Investigators Group for Lung Cancer and IIP. Miyamoto A, et al. Among authors: kishi k. Sci Rep. 2024 May 3;14(1):10162. doi: 10.1038/s41598-024-60833-w. Sci Rep. 2024. PMID: 38702426 Free PMC article.
Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non-small-cell lung cancer in KEYNOTE-407.
Sugawara S, Tanaka K, Imamura F, Yamamoto N, Nishio M, Okishio K, Hirashima T, Tanaka H, Fukuhara T, Nakahara Y, Kurata T, Katakami N, Okada M, Horinouchi H, Udagawa H, Kasahara K, Satouchi M, Saka H, Tokito T, Hosomi Y, Aoe K, Kishi K, Ohashi K, Yokoyama T, Adachi N, Noguchi K, Schwarzenberger P, Kato T. Sugawara S, et al. Among authors: kishi k. Cancer Sci. 2023 Aug;114(8):3330-3341. doi: 10.1111/cas.15816. Epub 2023 May 15. Cancer Sci. 2023. PMID: 37183528 Free PMC article. Clinical Trial.
First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study.
Imai H, Kijima T, Azuma K, Kishi K, Saito H, Yamaguchi T, Tanizaki J, Yoneshima Y, Fujita K, Watanabe S, Kitazono S, Fukuhara T, Hataji O, Toi Y, Mizutani H, Hamakawa Y, Maemondo M, Ohsugi T, Suzuki K, Horinouchi H, Ohe Y. Imai H, et al. Among authors: kishi k. Jpn J Clin Oncol. 2024 Apr 6;54(4):452-462. doi: 10.1093/jjco/hyad195. Jpn J Clin Oncol. 2024. PMID: 38271158 Free PMC article.
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, Shen Y, Kowanetz M, Lopez-Chavez A, Sandler A, Reck M; IMpower150 Study Group. Socinski MA, et al. N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4. N Engl J Med. 2018. PMID: 29863955 Free article. Clinical Trial.
A Prospective Phase II Trial of First-line Osimertinib for Patients with EGFR Mutation-positive Non-small Cell Lung Cancer and Poor Performance Status (OPEN/TORG2040).
Fukui T, Mamesaya N, Takahashi T, Kishi K, Yoshizawa T, Tokito T, Azuma K, Morikawa K, Igawa S, Okuma Y, Yamanaka Y, Hosokawa S, Kasai T, Masubuchi K, Nakamichi S, Aga M, Sasaki J, Kada A, Saito AM, Naoki K, Okamoto H; Thoracic Oncology Research Group (TORG). Fukui T, et al. Among authors: kishi k. J Thorac Oncol. 2025 Jan 2:S1556-0864(24)02548-6. doi: 10.1016/j.jtho.2024.12.027. Online ahead of print. J Thorac Oncol. 2025. PMID: 39755169
1,961 results